ARIBIOLAB

As of June 30, 2026, ARIBIOLAB carries a market capitalization of 78.98B, placing it among publicly traded companies globally. Its enterprise value stands at 69.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ARIBIOLAB has 26.87M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ARIBIOLAB maintains a current ratio of 1.92, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.57, indicating elevated leverage, while an interest coverage ratio of -7.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ARIBIOLAB posted a negative return on equity (ROE) of -92.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -44.96, reflecting losses generated across the asset base.

As of the close on October 23, 2026, ARIBIOLAB's stock has gained approximately 39.54% over the past 52 weeks. The 50-day moving average sits at 3,202.00, while the 200-day moving average is 3,037.69.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -12.55B, while operating income came in at -12.97B.

As of June 30, 2026, ARIBIOLAB holds 15.64B in cash and equivalents against 6.19B in total debt, resulting in a net debt position of -749.37M. Total book value stands at 9.89B, with working capital of 8.88B providing operational flexibility.

ARIBIOLAB produced -9.17B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -42.66M in capital expenditures, free cash flow totaled -9.22B - equivalent to -342.94 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.66: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 11.16, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ARIBIOLAB shareholders.